Loading...

TSHA TAYSHA GENE THERAPIES INC Earnings Calls 8-K Filing

TYSH

TSH

TAYSHA GENE THERAPIES INC

(TSHA)

2025 8-K

Financial Results Report

Sales Agreement Update

Rights Recovery

New Data Release

FDA Designation Update

Equity Offerings

Financial Updates

Product Expansion

Financial Statements

Financial Results

Financial Results

Financial Results

Public Offering

Public Offering

Clinical Data Announcement

Financial Results and Busin...

Financial Results and Updates

Equity Incentive Awards and...

Amendment to Increase Autho...

Financial Results and Busin...

Management Changes

Update on TSHA-120 Program ...

Other Special Situation

Private Placement of Common...

Delisting Notice

Clinical Updates

Board Composition and Compl...

Equity Incentive Awards and...

Presentation of Preclinical...

Financial Results and Busin...

Delisting and Board Resigna...

Financial Results and Busin...

Update on TSHA-120 Program ...

Departure of Chief Medical ...

External Links:

Taysha Gene Therapies, Inc. filed an amended 8-K on May 29, 2025, to correct typographical errors in its May 28 report, which included updates on the TSHA-102 trial for Rett Syndrome and announced the termination of a $100 million ATM prospectus for selling common stock.

AI Assistant

TAYSHA GENE THERAPIES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.